卡格列净和恩格列净对肥胖2型糖尿病患者的临床疗效

打开文本图片集

中图分类号：R587.1 文献标志码：A DOI：10.11958/20252351

HU Limei LIU Huiying CHEN Yaru ZHAO Panpan GU Jun REN Weidong

Clinical effcacy caragliflozin and empagliflozin in obese patients with type 2 diabetes mellitus ， ， ， ， ，

Abstract：ObjectiveTo analyze efects caragliflozinand empagliflozinon inflammatory markers，glucose and lipid metabolismandmiR-144expressioninobese patients with type2diabetes melitus （T2DM）.MethodsAtotal148obese T2DM patients admited toour hospitalfrom June 2O21 to May2O24 were selectedand divided intocaragliflozin group andempagliflozin groupbyrandom number tablemethod.The twogroupswere treatedwith canagliflozin and empagliflozinonbasisconventional treatmentfor6months.Theinflammatoryindicators，glucosemetabolism indicators，lipidmetabolismindicatos，micrRN-144 （miR-144）expreion，bodmassindex （BMI），clicalfcacyd incidence adverse reactions were comparedbetween two groups.ResultsAfteratotal 7cases were excluded during treatmentperiod，rewere71casesincaraglflozingroupand7Ocasesinempagliflozingroup.After treatment， levels tumor necrosis factor- α ，interleukin-6，C-reactive protein，fasting blood glucose （FBG），2 h postprandialbloodglucose（2-PPG），glycosylatedhemoglobin（HbAlc），riglyeride（TG），totalcholesterol，lowdesity lipoprotein cholesterol，BMIandmiR-144 expression werelowerthanthosebefore treatmentintwogroupspatients（ P< 0.05），and levels FBG， 2h -PPG，HbA1c，TG and miR-144 expression were lower in caragliflozin group than those empagliflozin group （ P<0.05 ）.After treatment，high density lipoprotein cholesterol was higher than that before treatment in two groups （ P<0.05 ），and that in canagliflozin group was higher than empagliflozin group （ P<0.05 ） There were nosignificantdifferences inclinical eficacyand incidenceadversereactionsbetweentwogroups after treatment （ P>0.05 ）.ConclusionBoth caragliflozin and empagliflozin have certain rapeutic eficacy and good safety for obese T2DM patients，and caragliflozin is more effective in improving glucose and lipid metabolism.

Key Words： diabetes mellitus，type 2; obesity; microRNAs; canagliflozin; empagliflozin

近年有文献报道，亚洲地区肥胖、2型糖尿病（T2DM）的患病率呈上升趋势[1]。（剩余11586字）